OncoSil announces new presentation of clinical outcomes data

Latest News

Medical device company OncoSil (ASX:OSL) has announced the findings of an oral presentation at The Mayo Clinic IMPACT Course 2023 by Dr Frank Weilert from Waikato Hospital in New Zealand.

The course was held in New York late last week.

The company said the oral presentation reviewed the clinical outcomes of 49 pancreatic cancer patients implanted with the OncoSil device at Royal Adelaide Hospital in Australia and Waikato Hospital. The patients were also treated with either FOLFIRINOX or gemcitabine and nab-paclitaxel chemotherapy.

The data presented showed local disease control in patients 12 weeks post-implant was 96 per cent, 15 patients (31 per cent) had tumour downstaging and were technically resectable, and the technical success of OncoSil implantation was 100 per cent with no acute complications.

OncoSil CEO and managing director Nigel Lange said, “The presentation of this data covering two treatment centres in Australia and New Zealand demonstrates the key benefits of the OncoSil™ device for patients with Locally Advanced Pancreatic Cancer.”